Securities Code: 300199
Securities Abbreviation: Han Yu Pharmaceutical
Announcement Number: 2026-039
Shenzhen Han Yu Pharmaceutical Co., Ltd.
Announcement on Uncovered Losses Exceeding One-Third of Paid-in Capital
The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or material omissions.
Shenzhen Han Yu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the fifteenth meeting of the Sixth Board of Directors on July 1, 2026, and approved the "Proposal on Uncovered Losses Exceeding One-Third of Paid-in Capital." This proposal will be submitted to the Company's third extraordinary general meeting of shareholders in 2026 for review. The relevant situation is hereby announced as follows:
I. Overview
According to the "Audit Report" issued by Zhengdazhiyuan (Shenzhen) Certified Public Accountants (Special General Partnership), as of December 31, 2025, the Company's consolidated financial statements for 2025 showed undistributed profits of -1,813,796,112.86 yuan, and the Company's paid-in capital was 883,241,336.00 yuan. The Company's uncovered losses have exceeded one-third of its paid-in capital. In accordance with the "Company Law of the People's Republic of China" and the "Articles of Association," when uncovered losses reach one-third of the paid-in capital, the matter must be submitted to the Company's shareholders' meeting for review.
II. Reasons for Uncovered Losses